Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
28 Results for "
Lipid metabolic disorders
" in MedChemExpress (MCE) Product Catalog:
Products (28)
28 Results for "Lipid metabolic disorders" in MCE Product Catalog:
6
2
2 Cited Publications
Synonyms: Dioctyl sulfosuccinate sodium salt
Target:
Research Areas:
Docusate Sodium (Dioctyl sulfosuccinate sodium salt) is one of the main components in stool softeners. Docusate Sodium is a sulfated surfactant and may inactivate viral pathogens by disrupting viral envelopes and/or denaturing/disassociating proteins. Docusate Sodium is effective in vitro against wild type and drug-resistant strains of HSV type 1 and 2. Docusate Sodium is an obesogen. Docusate Sodium with developmental exposure leads to increased adult adiposity, inflammation, metabolic disorder and dyslipidemia in offspring fed a standard diet in mice .
2
Research Areas:
1
1 Cited Publications
Cat. No.: HY-P2048
CAS No.: 1627580-64-6
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology
MOTS-c (human) is a mitochondrial-derived peptide that modulates the AMPK/PGC-1α pathway to enhance insulin sensitivity. MOTS-c (human) inhibits the folate cycle and de novo purine synthesis, increases AICAR levels to activate AMPK, and then regulates the Nrf2/Keap1 antioxidant pathway and inhibits the NF-κB inflammatory pathway, while promoting mitochondrial biogenesis and energy metabolism. MOTS-c (human) has the effects of improving glucose and lipid metabolism, anti-oxidative stress, anti-inflammatory and neuroprotection, and can be used in the study of type 2 diabetes, traumatic brain injury, inflammatory diseases and aging-related metabolic disorders .
1
1 Cited Publications
Cat. No.: HY-P2048A
Research Areas:
MOTS-c (human) acetate is a mitochondrial-derived peptide that modulates the AMPK/PGC-1α pathway to enhance insulin sensitivity. MOTS-c (human) acetate inhibits the folate cycle and de novo purine synthesis, increases AICAR levels to activate AMPK, and then regulates the Nrf2/Keap1 antioxidant pathway and inhibits the NF-κB inflammatory pathway, while promoting mitochondrial biogenesis and energy metabolism. MOTS-c (human) acetate has the effects of improving glucose and lipid metabolism, anti-oxidative stress, anti-inflammatory and neuroprotection, and can be used in the study of type 2 diabetes, traumatic brain injury, inflammatory diseases and aging-related metabolic disorders .
Target:
Research Areas:
LysoPE (18:2/0:0) is a lysophosphatidylethanolamine implicated in phospholipid metabolism. LysoPE (18:2/0:0) shows significantly altered serum levels in mice exposed to a combination of DEHP (HY-B1945) and Aroclor 1254, which is associated with disturbed phospholipid metabolism. LysoPE (18:2/0:0) can be used for the research of endocrine-disrupting compound-induced metabolic disorders and lipid metabolism disturbance. LysoPE (18:2/0:0) is identified as a potential biomarker for the combined toxicity of DEHP and Aroclor 1254 .
Target:
Research Areas:
Docusate (Sodium) (Standard) is the analytical standard of Docusate (Sodium). This product is intended for research and analytical applications. Docusate Sodium (Dioctyl sulfosuccinate sodium salt) is one of the main components in stool softeners. Docusate Sodium is a sulfated surfactant and may inactivate viral pathogens by disrupting viral envelopes and/or denaturing/disassociating proteins. Docusate Sodium is effective in vitro against wild type and drug-resistant strains of HSV type 1 and 2. Docusate Sodium is an obesogen. Docusate Sodium with developmental exposure leads to increased adult adiposity, inflammation, metabolic disorder and dyslipidemia in offspring fed a standard diet in mice .
Cat. No.: HY-163436
CAS No.: 1338190-14-9
Target:
Research Areas:
F44-A13 is an orally active and highly selective farnesoid X receptor (FXR) antagonist with an IC50 value of 1.1 μM. F44-A13 can optimize cholesterol metabolism and reduce its activity by inducing CYP7A1 expression. F44-A13 reduces levels of cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) in mouse models. F44-A13 can be used in the study of metabolic diseases associated with lipid disorders .
Cat. No.: HY-145392
CAS No.: 2711039-08-4
Target:
Research Areas:
ACSS2-IN-1 is a potent acetyl-CoA synthetase 2 (ACSS2) inhibitor with an IC50 of <1 nM. ACSS2-IN-1 inhibits ACSS2 enzymatic activity, blocks the metabolic pathway converting acetate to acetyl-CoA in cancer cells, and thereby suppresses tumor energy metabolism, lipid synthesis and histone acetylation. ACSS2-IN-1 can be used in the research of cancer and hyperproliferative disorders .
Cat. No.: HY-178794
CAS No.: 3038861-75-2
Target:
Research Areas:
AGU661 is a Microsomal prostaglandin E2 synthase 1 (mPGES-1) inhibitor with an IC50 of 0.22 nM. AGU661 lowers PGE2 formation in human pro-inflammatory M1 macrophages and activated monocytes without affecting other lipid mediator pathways. AGU661 has unfavorable physicochemical properties with poor metabolic stability and strong plasma protein binding tendencies. AGU661 into PLGA-based NPs significantly enhances its bioactivity. AGU661 can be used for inflammatory disorders research .
Cat. No.: HY-178780
CAS No.: 2137977-29-6
Synonyms: MKP10241
Target:
Research Areas:
Deziglipel (MKP10241) is an orally active GPR119 agonist (human EC50: 3.7 nM; IC50 > 7.2 μM). Deziglipel activates GPR119 to increase cAMP levels, promotes active GLP-1 release, reduces blood glucose and HbA1c, decreases body weight and feed intake, and resolves MASH via altered lipid, cytokine, and liver enzyme levels. Deziglipel shows low hERG channel inhibition, minimal CYP450 inhibition, no PXR activation, and no significant transporter inhibition. Deziglipel can be used for the research of type 2 diabetes mellitus, obesity, MASH/MASLD, and metabolic disorders .
Cat. No.: HY-N8466
CAS No.: 143236-02-6
Target:
Cat. No.: HY-P1723A
Synonyms: Neuropeptide Q TFA
Research Areas:
Cat. No.: HY-111327
CAS No.: 83470-79-5
Target:
Research Areas:
Valibose is analpha-glucosidaseinhibitor, and ameliorates the metabolic disorder of glucose and lipids and the nephropathy in Streptozotocin (HY-13753)-induced diabetic rats .
NSC 48160 inhibits the growth of the pancreatic cancer cells with IC50s of 84.3 μM for CPFAC-1 and 94.5 μM for BxPC-3. NSC 48160 also induces pancreatic cancer cell apoptosis. NSC 48160 can improve metabolic syndromes, such as NASH, obesity and lipid metabolism disorders .
Cat. No.: HY-N13198
CAS No.: 356517-93-6
Target:
Cat. No.: HY-N11507
CAS No.: 2319668-87-4
Synonyms: TKV
Target:
Cat. No.: HY-187385
Target:
Research Areas:
GPR35 agonist 8 is a cross-species, highly potent GPR35 agonist (human EC50: 12 nM; murine EC50: 2 nM). GPR35 agonist 8 reduces lipid accumulation, ameliorates lipid metabolism disorders, alleviates hepatic inflammation and liver fibrosis, and relieves hepatic steatosis. GPR35 agonist 8 can be used for research on metabolic dysfunction-associated fatty liver disease and metabolic dysfunction-associated steatohepatitis .
Cat. No.: HY-W002852
CAS No.: 68208-18-4
Synonyms: 3-Amino-3-(4-methylphenyl)propanoic acid
Target:
Research Areas:
3-Amino-3-(p-tolyl) propionic acid (3-Amino-3-(4-methylphenyl) propanoic acid) is a GPR40 agonist. 3-Amino-3-(p-tolyl) propionic acid is used for research on type 2 diabetes, obesity, metabolic syndrome and lipid disorders .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
